YNIOS Pharma
La probabilité de faillite calculée de YNIOS Pharma sur 12 mois est de 0,7% (faible). Les comptes annuels de 2024 montrent des capitaux propres de €702k et un résultat net de €342k. Les capitaux propres progressent d'environ 417,3 % par an sur les exercices déposés. L'entreprise est active depuis 2022 et le Moniteur belge ne contient aucun signal d'insolvabilité ou d'avertissement.
| Capitaux propres | €702k |
| Résultat net | €342k |
| Active | 4 ans |
| Publications | 6 |
Profil exceptionnel — solide sur presque tous les axes.
Estimation statistique fondée sur des sources publiques — pas un conseil de crédit ni une constatation. Comment calculons-nous cela ?
Le détail complet du score, son historique par exercice et la limite de crédit indicative se débloquent à partir de Starter.
Voir les plans →Comment calculons-nous cela ?
La tendance est une médiane robuste de toutes les pentes par paires d'exercices (Theil–Sen), de sorte qu'une seule année atypique ne peut pas détourner la ligne. Pour les séries strictement positives, nous calculons aussi une variante log (croissance annuelle composée) et retenons celle qui décrit le mieux les chiffres.
La zone autour de la projection vaut 1,8 × l'écart absolu médian par rapport à la tendance et s'élargit chaque année (×1 / ×1,6 / ×2,2), avec un minimum de 8 % de la dernière valeur. C'est une marge indicative, pas un intervalle de confiance statistique.
Une série dont les écarts dépassent 35 % du niveau est trop volatile : nous ne montrons alors délibérément aucune projection. Toute projection suppose une politique inchangée et ignore les informations non publiques (carnet de commandes, contrats, levées de fonds).
| Exercice | 2024 |
|---|---|
| Chiffre d'affaires | — |
| EBITDA | €392k |
| Résultat net | €342k |
| Cash-flow | €392k |
| Frais de personnel | — |
| Impôts sur le résultat | — |
| Dividendes | — |
| Total actif | €970k |
| Capitaux propres | €702k |
| Dettes | €268k |
| dont ≤ 1 an | €268k |
| dont > 1 an | — |
| Fonds de roulement | €-1k |
| Employés (ETP) | — |
| 2024 | |
|---|---|
| Current ratio | 0,99 |
| Quick ratio | 0,99 |
| Ratio fonds de roulement | -0,1% |
| Solvabilité | 72,4% |
| Debt / equity | 0,38 |
| Endettement à long terme | — |
| Interest coverage | 326,29 |
| Rentabilité brute | — |
| Rentabilité nette | — |
| ROA | 35,3% |
| ROE | 48,7% |
| Marge EBITDA | — |
| Crédit clients (DSO) | — |
| Crédit fournisseurs (DPO) | — |
| Rotation des stocks | — |
| Jours de stock (DSI) | — |
| Poste | Code | 2024 |
|---|---|---|
| Bilan — Actif | ||
| TOTAL DE L'ACTIF | 20/58 | €970k |
| Actifs immobilisés | 21/28 | €704k |
| Immobilisations incorporelles | 21 | €704k |
| Actifs circulants | 29/58 | €266k |
| Créances à un an au plus | 40/41 | €9k |
| Valeurs disponibles | 54/58 | €257k |
| Bilan — Passif | ||
| TOTAL DU PASSIF | 10/49 | €970k |
| Capitaux propres | 10/15 | €702k |
| Apport / capital | 10/11 | €692k |
| Bénéfice (perte) reporté(e) | 14 | €11k |
| Dettes | 17/49 | €268k |
| Dettes à un an au plus | 42/48 | €268k |
| Dettes commerciales à un an au plus | 44 | €7k |
| Compte de résultats | ||
| Marge brute d'exploitation | 9900 | €393k |
| Résultat d'exploitation | 9901 | €343k |
| Produits financiers | 75 | €236 |
| Charges financières | 65 | €1k |
| Résultat avant impôts | 9903 | €342k |
| Résultat de l'exercice | 9904 | €342k |
| Résultat à affecter | 9905 | €342k |
| NACE primaire | 20420 |
| Forme juridique | SRL(610) |
| Date de constitution | 16-03-2022 |
| Status | Actif |
| Code postal | 4537 |
Une seule chronologie de tout ce qui est arrivé à cette entreprise — publications, événements d'insolvabilité et de cycle de vie, changements administratifs et comptes annuels déposés.
06-12-2024 Restructuration des classes d'actions
Détails techniques
{
"events": [
{
"kind": "share_class_creation",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"subscribers": [
{
"kbo": "0538.839.354",
"rrn": null,
"kind": "org",
"name": "SPREDS FINANCE",
"share_class": "B1",
"liberation_pct": 100.0,
"contribution_kind": "geld",
"n_shares_subscribed": 74500,
"contribution_amount_eur": 74500.0
}
],
"share_emission": {
"agio_eur": 0.0,
"share_form": "no_nominal_value",
"share_class": "B1",
"n_new_shares": 74500,
"with_new_shares": true,
"nominal_value_eur": null,
"issue_price_per_share_eur": 1.0
},
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "share_class_conversion",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"subscribers": [
{
"kbo": null,
"rrn": null,
"kind": "person",
"name": "Pascal VAN HOVE",
"share_class": null,
"liberation_pct": null,
"contribution_kind": null,
"n_shares_subscribed": null,
"contribution_amount_eur": null
}
],
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
}
],
"notary": {
"name": "David REMY",
"firm_city": null,
"firm_name": null,
"office_city": "Fernelmont",
"is_associated": false
},
"act_meta": {
"language": "fr",
"pub_date": "2024-12-06",
"filing_date": "2024-12-03",
"act_kind_objet": "Objet de l\u0027acte:"
},
"decision": {
"body": "assembl\u00E9e_g\u00E9n\u00E9rale_extraordinaire",
"act_date": "2024-08-08",
"unanimous": null,
"under_authorized_capital": false,
"underlying_resolution_date": null
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0783.494.239",
"name_full": "YNIOS Pharma",
"legal_form": "Soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e",
"is_foreign_registered": false
},
"publication_proxy": {
"kind": "none",
"org_kbo": null,
"org_name": null,
"person_name": null,
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [],
"shareholders_after": [
{
"kbo": "0538.839.354",
"pct": null,
"kind": "org",
"name": "SPREDS FINANCE",
"role": "aandeelhouder",
"n_shares": 74500,
"share_class": "B1"
},
{
"kbo": null,
"pct": null,
"kind": "person",
"name": "Pascal VAN HOVE",
"role": "aandeelhouder",
"n_shares": 87400,
"share_class": "B2"
}
],
"share_classes_after": [
{
"n_shares": 5370000,
"class_name": "A",
"capital_share_eur": null,
"voting_rights_per_share": 1.0
},
{
"n_shares": 187100,
"class_name": "B1",
"capital_share_eur": null,
"voting_rights_per_share": 1.0
},
{
"n_shares": 300000,
"class_name": "B2",
"capital_share_eur": null,
"voting_rights_per_share": 1.0
},
{
"n_shares": 2700,
"class_name": "B3",
"capital_share_eur": null,
"voting_rights_per_share": 1.0
},
{
"n_shares": 200000,
"class_name": "B4",
"capital_share_eur": null,
"voting_rights_per_share": 1.0
}
]
}06-12-2024 Modification des statuts — traduction des statuts, coordination des statuts et modification d'articles spécifiques
Détails techniques
{
"notary": {
"name": "David REMY",
"firm_city": null,
"firm_name": null,
"office_city": "Fernelmont",
"is_associated": false
},
"act_meta": {
"language": "fr",
"pub_date": "2024-12-06",
"filing_date": "2024-12-03",
"act_kind_objet": "STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS), CAPITAL, ACTIONS, DIVERS"
},
"decision": {
"body": "buitengewone_algemene_vergadering",
"act_date": "2024-08-08",
"unanimous": null
},
"statute_change": {
"kinds": [
"translation",
"coordination",
"targeted_amendment"
],
"scope": "full_restatement",
"trigger": "wvv_adaptation",
"language_after": "fr",
"language_before": "fr"
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0783.494.239",
"name_full_after": "YNIOS Pharma",
"legal_form_after": "Soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e",
"name_full_before": "YNIOS Pharma",
"current_zetel_raw": "Chemin de l\u2019Yerne, 6C 4537 Verlaine",
"legal_form_before": "Soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e"
},
"special_mandates": [
{
"holder_kbo": null,
"holder_name": "David REMY",
"scope_categories": [
"publication"
],
"with_substitution": true
}
],
"articles_modified": [
{
"summary": "Remplace le texte de l\u0027article 5 des statuts par un nouveau texte d\u00E9taillant l\u0027\u00E9mission et la r\u00E9partition des actions en cinq cat\u00E9gories.",
"new_text": "Article 5. Apports\nEn r\u00E9mun\u00E9ration des apports, 6.059.800 actions ont \u00E9t\u00E9 \u00E9mises, r\u00E9parties en 5 cat\u00E9gories :\n \u2022 5.370.000 actions de cat\u00E9gorie A (FONDATEURS) ;\n \u2022 187.100 actions de cat\u00E9gorie B1 (SPREDS FINANCE Tax Shelter) ;\n \u2022 300.000 actions de cat\u00E9gorie B2 (PRIVES Tax Shelter) ;\n \u2022 2.700 actions de cat\u00E9gorie B3 (SPREDS FINANCE Normal) ;\n \u2022 200.000 actions de cat\u00E9gorie B4 (PRIVES Normal).\nChaq",
"change_kind": "replaced",
"article_title": "Apports",
"article_number": "5"
}
],
"governance_change": null,
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "David REMY",
"org_rep_person_name": null
},
"co_filed_documents": [],
"shareholder_rights": {
"quorum_rules_changed": false,
"liquidation_preference_text": null,
"voorkeurrecht_rules_changed": true,
"aandelenoverdracht_restrictions_changed": false
},
"voorwerp_change_summary": null,
"capital_structure_change": {
"operations": [
"share_class_creation"
],
"split_ratio": null,
"shares_after": null,
"shares_before": null,
"capital_after_eur": null,
"capital_before_eur": null,
"share_classes_after": [
{
"count": 74500,
"label": "B1",
"rights_summary": "Souscription nouvelle, r\u00E9gime Tax Shelter",
"voting_per_share": null
},
{
"count": 300000,
"label": "B2",
"rights_summary": "PRIVES Tax Shelter",
"voting_per_share": null
},
{
"count": 2700,
"label": "B3",
"rights_summary": "SPREDS FINANCE Normal",
"voting_per_share": null
},
{
"count": 200000,
"label": "B4",
"rights_summary": "PRIVES Normal",
"voting_per_share": null
}
]
},
"coordinated_text_lineage": null
}10-06-2024 Publication au Moniteur belge — Divers
Détails techniques
{
"stage": null,
"notary": {
"name": "David REMY",
"firm_city": null,
"firm_name": null,
"office_city": "Fernelmont",
"is_associated": false
},
"act_meta": {
"language": "nl",
"pub_date": "2024-06-10",
"filing_date": "2024-06-06",
"act_kind_objet": "STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS), CAPITAL, ACTIONS, DIVERS"
},
"decision": {
"body": "algemene_vergadering",
"act_date": "2024-03-19",
"unanimous": null
},
"conversion": {
"effective_date": null,
"jurisdiction_to": null,
"legal_form_after": null,
"jurisdiction_from": null,
"legal_form_before": "Soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e"
},
"detected_kind": "conversion_legal_form",
"report_waiver": {
"summary": "The shareholders waived their preferential subscription right under article 7 of the statutes.",
"articles": [
"7"
]
},
"restructuring": {
"parties": [
{
"kbo": "0783.494.239",
"name": "YNIOS Pharma",
"role": "contributor",
"address": "Chemin de l\u2019Yerne, 6C, 4537 Verlaine",
"is_foreign": false,
"legal_form": "Soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e",
"is_new_company": false,
"jurisdiction_country": null
},
{
"kbo": "0538.839.354",
"name": "SPREDS FINANCE",
"role": "contributor",
"address": null,
"is_foreign": false,
"legal_form": "soci\u00E9t\u00E9 anonyme",
"is_new_company": false,
"jurisdiction_country": null
},
{
"kbo": null,
"name": "Pascal VAN HOOVE",
"role": "contributor",
"address": null,
"is_foreign": false,
"legal_form": null,
"is_new_company": false,
"jurisdiction_country": null
},
{
"kbo": null,
"name": "Ilse DE GROOTE",
"role": "contributor",
"address": null,
"is_foreign": false,
"legal_form": null,
"is_new_company": false,
"jurisdiction_country": null
}
],
"exchange_ratio": null,
"legal_articles": [
"7"
],
"is_cross_border": false,
"is_silent_merger": false,
"balance_basis_date": null,
"exchange_ratio_text": null,
"new_shares_issued_n": 5985300,
"real_estate_included": false,
"patrimony_description": null,
"equity_transferred_eur": null,
"accounting_effective_date": null
},
"subject_company": {
"kbo": "0783.494.239",
"name_full": "YNIOS Pharma",
"legal_form": "Soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e"
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "David REMY",
"org_rep_person_name": null
},
"summary_narrative": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale extraordinaire de YNIOS Pharma a pris des r\u00E9solutions pour augmenter le nombre d\u0027actions, cr\u00E9er de nouvelles cat\u00E9gories d\u0027actions et souscrire \u00E0 ces nouvelles actions aupr\u00E8s de partenaires certifi\u00E9s et d\u0027investisseurs priv\u00E9s. Parall\u00E8lement, les statuts ont \u00E9t\u00E9 modifi\u00E9s pour refl\u00E9ter ces apports.",
"co_filed_documents": [],
"detected_real_type": "other",
"referenced_correction": {
"prior_pub_date": "2022-03-18",
"what_corrected": null,
"prior_pub_number": "22318105"
},
"should_reroute_to_category": null
}10-06-2024 Restructuration des classes d'actions
Détails techniques
{
"events": [
{
"kind": "share_class_creation",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"subscribers": [
{
"kbo": "0538.839.354",
"rrn": null,
"kind": "org",
"name": "SPREDS FINANCE",
"share_class": "B1",
"liberation_pct": 100.0,
"contribution_kind": null,
"n_shares_subscribed": 7600,
"contribution_amount_eur": null
}
],
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": "B1",
"n_new_shares": 7600,
"with_new_shares": true,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "share_class_creation",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"subscribers": [
{
"kbo": "0538.839.354",
"rrn": null,
"kind": "org",
"name": "SPREDS FINANCE",
"share_class": "B2",
"liberation_pct": 100.0,
"contribution_kind": null,
"n_shares_subscribed": 87400,
"contribution_amount_eur": null
}
],
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": "B2",
"n_new_shares": 87400,
"with_new_shares": true,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": 87400,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "share_class_creation",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"subscribers": [
{
"kbo": "0538.839.354",
"rrn": null,
"kind": "org",
"name": "SPREDS FINANCE",
"share_class": "B3",
"liberation_pct": 100.0,
"contribution_kind": null,
"n_shares_subscribed": 2700,
"contribution_amount_eur": null
}
],
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": "B3",
"n_new_shares": 2700,
"with_new_shares": true,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": 2700,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "share_class_creation",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"subscribers": [
{
"kbo": null,
"rrn": null,
"kind": "person",
"name": "Pascal VAN HOOVE",
"share_class": "B4",
"liberation_pct": 100.0,
"contribution_kind": null,
"n_shares_subscribed": 87600,
"contribution_amount_eur": null
},
{
"kbo": null,
"rrn": null,
"kind": "person",
"name": "Ilse DE GROOTE",
"share_class": "B4",
"liberation_pct": 100.0,
"contribution_kind": null,
"n_shares_subscribed": 25000,
"contribution_amount_eur": null
}
],
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": "B4",
"n_new_shares": 112600,
"with_new_shares": true,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": 112600,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "share_class_creation",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
}
],
"notary": {
"name": "David REMY",
"firm_city": null,
"firm_name": null,
"office_city": "Fernelmont",
"is_associated": false
},
"act_meta": {
"language": "fr",
"pub_date": "2024-06-10",
"filing_date": "2024-06-06",
"act_kind_objet": "Objet de l\u0027acte:"
},
"decision": {
"body": "assembl\u00E9e_generale_extraordinaire",
"act_date": "2024-03-19",
"unanimous": null,
"under_authorized_capital": false,
"underlying_resolution_date": null
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0783.494.239",
"name_full": "YNIOS Pharma",
"legal_form": "Soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e",
"is_foreign_registered": false
},
"publication_proxy": {
"kind": "none",
"org_kbo": null,
"org_name": null,
"person_name": null,
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [],
"shareholders_after": [
{
"kbo": "0538.839.354",
"pct": null,
"kind": "org",
"name": "SPREDS FINANCE",
"role": null,
"n_shares": 5370000,
"share_class": "A"
},
{
"kbo": "0538.839.354",
"pct": null,
"kind": "org",
"name": "SPREDS FINANCE",
"role": null,
"n_shares": 112600,
"share_class": "B1"
},
{
"kbo": "0538.839.354",
"pct": null,
"kind": "org",
"name": "SPREDS FINANCE",
"role": null,
"n_shares": 387400,
"share_class": "B2"
},
{
"kbo": "0538.839.354",
"pct": null,
"kind": "org",
"name": "SPREDS FINANCE",
"role": null,
"n_shares": 2700,
"share_class": "B3"
},
{
"kbo": null,
"pct": null,
"kind": "person",
"name": "Pascal VAN HOOVE",
"role": null,
"n_shares": 87600,
"share_class": "B4"
},
{
"kbo": null,
"pct": null,
"kind": "person",
"name": "Ilse DE GROOTE",
"role": null,
"n_shares": 25000,
"share_class": "B4"
}
],
"share_classes_after": [
{
"n_shares": 5370000,
"class_name": "A",
"capital_share_eur": null,
"voting_rights_per_share": 1.0
},
{
"n_shares": 112600,
"class_name": "B1",
"capital_share_eur": null,
"voting_rights_per_share": 1.0
},
{
"n_shares": 387400,
"class_name": "B2",
"capital_share_eur": null,
"voting_rights_per_share": 1.0
},
{
"n_shares": 2700,
"class_name": "B3",
"capital_share_eur": null,
"voting_rights_per_share": 1.0
},
{
"n_shares": 112600,
"class_name": "B4",
"capital_share_eur": null,
"voting_rights_per_share": 1.0
}
]
}25-01-2023 Restructuration des classes d'actions
Détails techniques
{
"events": [
{
"kind": "share_class_conversion",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": 5575000,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "share_class_creation",
"after_eur": null,
"delta_eur": 200000.0,
"before_eur": null,
"subscribers": [
{
"kbo": null,
"rrn": null,
"kind": "person",
"name": "PASCAL VAN HOVE",
"share_class": "B2",
"liberation_pct": 100.0,
"contribution_kind": "geld",
"n_shares_subscribed": 100000,
"contribution_amount_eur": 100000.0
},
{
"kbo": null,
"rrn": null,
"kind": "person",
"name": "Madame DE GROOTE Ilse Leonce",
"share_class": "B2",
"liberation_pct": 100.0,
"contribution_kind": "geld",
"n_shares_subscribed": 100000,
"contribution_amount_eur": 100000.0
}
],
"share_emission": {
"agio_eur": 0.0,
"share_form": null,
"share_class": "B2",
"n_new_shares": 200000,
"with_new_shares": true,
"nominal_value_eur": null,
"issue_price_per_share_eur": 1.0
},
"decrease_purpose": null,
"contribution_type": "geld",
"paid_up_delta_eur": 200000.0,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "statutory_reserve_release",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": "convert_to_apports_non_appeles"
},
{
"kind": "other",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
}
],
"notary": {
"name": "David REMY",
"firm_city": null,
"firm_name": null,
"office_city": "Fernelmont",
"is_associated": false
},
"act_meta": {
"language": "fr",
"pub_date": "2023-01-25",
"filing_date": "2023-01-23",
"act_kind_objet": "Objet de l\u0027acte:"
},
"decision": {
"body": "assembl\u00E9e g\u00E9n\u00E9rale extraordinaire",
"act_date": "2023-01-17",
"unanimous": null,
"under_authorized_capital": false,
"underlying_resolution_date": null
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0783.494.239",
"name_full": "YNIOS Pharma",
"legal_form": "Soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e",
"is_foreign_registered": false
},
"publication_proxy": {
"kind": "none",
"org_kbo": null,
"org_name": null,
"person_name": null,
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [],
"shareholders_after": [],
"share_classes_after": [
{
"n_shares": 5370000,
"class_name": "A",
"capital_share_eur": null,
"voting_rights_per_share": 1.0
},
{
"n_shares": 105000,
"class_name": "B1",
"capital_share_eur": null,
"voting_rights_per_share": 1.0
},
{
"n_shares": 300000,
"class_name": "B2",
"capital_share_eur": null,
"voting_rights_per_share": 1.0
}
]
}28-09-2022 Restructuration des classes d'actions
Détails techniques
{
"events": [
{
"kind": "share_class_creation",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "share_class_creation",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "share_class_creation",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "share_transfer",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"subscribers": [
{
"kbo": null,
"rrn": null,
"kind": "org",
"name": "SPREDS FINANCE",
"share_class": "B1",
"liberation_pct": 100.0,
"contribution_kind": "geld",
"n_shares_subscribed": 105000,
"contribution_amount_eur": 105000.0
},
{
"kbo": null,
"rrn": null,
"kind": "person",
"name": "VAN HOVE Pascal Urbain",
"share_class": "B2",
"liberation_pct": 100.0,
"contribution_kind": "geld",
"n_shares_subscribed": 100000,
"contribution_amount_eur": 100000.0
}
],
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "statutory_reserve_release",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": "convert_to_distributable"
}
],
"notary": {
"name": "David REMY",
"firm_city": null,
"firm_name": null,
"office_city": "Fernelmont",
"is_associated": false
},
"act_meta": {
"language": "fr",
"pub_date": "2022-09-28",
"filing_date": "2022-09-26",
"act_kind_objet": "Objet de l\u0027acte:"
},
"decision": {
"body": "assembl\u00E9e_generale_extraordinaire",
"act_date": "2022-09-06",
"unanimous": null,
"under_authorized_capital": false,
"underlying_resolution_date": null
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0783.494.239",
"name_full": "YNIOS Pharma",
"legal_form": "Soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e",
"is_foreign_registered": false
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "Ghislaine",
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [],
"shareholders_after": [
{
"kbo": "0783.494.239",
"pct": null,
"kind": "org",
"name": "YNIOS Pharma",
"role": "aandeelhouder",
"n_shares": 5370000,
"share_class": "A"
},
{
"kbo": null,
"pct": null,
"kind": "org",
"name": "SPREDS FINANCE",
"role": "aandeelhouder",
"n_shares": 105000,
"share_class": "B1"
},
{
"kbo": null,
"pct": null,
"kind": "person",
"name": "VAN HOVE Pascal Urbain",
"role": "aandeelhouder",
"n_shares": 100000,
"share_class": "B2"
}
],
"share_classes_after": [
{
"n_shares": 5370000,
"class_name": "A",
"capital_share_eur": null,
"voting_rights_per_share": 1.0
},
{
"n_shares": 105000,
"class_name": "B1",
"capital_share_eur": null,
"voting_rights_per_share": 1.0
},
{
"n_shares": 100000,
"class_name": "B2",
"capital_share_eur": null,
"voting_rights_per_share": 1.0
}
]
}Générez une note structurée et factuelle à partir de tous les signaux de ce dossier : risque, santé financière, structure de propriété, mandats et comparaison sectorielle.
| Dénomination légaleFR | YNIOS Pharma |